Pharmabiz14d
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer
Professor Martin Reck, Head of the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf, Germany, member of the AEGEAN Steering Committee and investigator in the trial, said: “Adding ...
EU set to approve AstraZeneca’s Imfinzi-chemo combo for NSCLC
AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation for approval in the ...
Medical Dialogues14d
AstraZeneca Imfinzi based perioperative regimen recommended for approval in EU for resectable non-small cell lung cancer
AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...
Health And Pharma15d
CHMP Recommends Durvalumab Combination for EU Approval in Resectable NSCLC
AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...
gut.bmj15d
Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC. Objective ...
London South East15d
AstraZeneca lung cancer therapy Imfinzi recommended for EU approval
The Cambridge, England-based pharmaceuticals firm said Imfinzi, or durvalumab, in combination ... and was based on results from the Aegean phase three trial. In the trial, the drug showed a ...
Buy15d
AstraZeneca lung cancer therapy Imfinzi recommended for EU approval
The Cambridge, England-based pharmaceuticals firm said Imfinzi, or durvalumab, in combination with chemotherapy ... and was based on results from the Aegean phase three trial. In the trial, the drug ...
PharmiWeb15d
Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable non-small cell lung cancer
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...